Literature DB >> 2386447

Differential effects of scopolamine and amphetamine on microcomputer-based performance tests.

R S Kennedy1, R C Odenheimer, D R Baltzley, W P Dunlap, C D Wood.   

Abstract

Scopolamine (1.0 mg) and d-amphetamine (10 mg) were administered alone and in combination to 16 subjects (medical students), randomly assigned to testing sessions in a fully crossed-over (Latin square) within-subjects design. After being practiced to stability, 9 performance tests from a menu of portable microcomputer-based tests were administered double-blind over 4 weekly treatments (including a placebo). Differential effects of drugs on performance were found. Motor and perceptual speed tests appeared enhanced by d-amphetamine and not degraded by scopolamine. Two of the five cognitive tests showed reductions with scopolamine. The findings are discussed in connection with using a menu of performance tests that can have diagnostic significance for assessment of drug treatments. The effects of scopolamine in this study and others are considered in terms of a model which implies that magnitude of performance deficit depends on performance type (cognitive, motor, self-report) and dosage level. Applying the model, we offer the following summary: below 0.15 mg scopolamine is without any effect; below 0.50 mg, the effect is limited, but can be revealed by some sensitive, complex performance tests and self-report; above 1.0 mg, the effect is likely to impact on operational efficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386447

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  8 in total

1.  Effects of single and repeated doses of theophylline on aspects of performance, electrophysiology and subjective assessments in healthy human subjects.

Authors:  P Bartel; R Delport; B Lotz; J Ubbink; P Becker
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Amphetamine self-administration by humans: modulation by contingencies associated with task performance.

Authors:  S D Comer; M Haney; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 3.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 4.  Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals.

Authors:  M Elizabeth Smith; Martha J Farah
Journal:  Psychol Bull       Date:  2011-09       Impact factor: 17.737

5.  The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance.

Authors:  Beata Y Silber; Rodney J Croft; Katherine Papafotiou; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2006-06-08       Impact factor: 4.530

Review 6.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  Brain Behav       Date:  2012-07-23       Impact factor: 2.708

8.  A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal.

Authors:  Miriam Z Mintzer; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2007-03-07       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.